PB2535: TRIAL IN PROGRESS: A PHASE 2, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LUSPATERCEPT TO TREAT ANEMIA IN ADULTS WITH ALPHA-THALASSEMIA
Vip Viprakasit,
Yongrong Lai,
Gian Luca Forni,
Meng-Yao Lu,
Liudi Yang,
Wenhui Shi,
Loyse Felber Medlin,
Frederik Lersch,
Jeevan K. Shetty,
Luciana Moro Bueno,
Richard Wei,
Antonis Kattamis
Affiliations
Vip Viprakasit
1 Siriraj Research Hospital, Mahidol University, Bangkok, Thailand
Yongrong Lai
2 First Affiliated Hospital of Guangxi Medical University, Nanning, China
Gian Luca Forni
3 Ospedale Galliera, Centro della Microcitemia e Anemie Congenite e del Dismetabolismo del Ferro, Genoa, Italy
Meng-Yao Lu
4 National Taiwan University Hospital, Taipei City, Taiwan
Liudi Yang
5 Bristol Myers Squibb, Shanghai, China
Wenhui Shi
5 Bristol Myers Squibb, Shanghai, China
Loyse Felber Medlin
6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
Frederik Lersch
6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
Jeevan K. Shetty
6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
Luciana Moro Bueno
6 Celgene International Sàrl, a Bristol-Myers Squibb Company, Boudry, Switzerland
Richard Wei
7 Bristol Myers Squibb, Princeton, NJ, United States
Antonis Kattamis
8 National and Kapodistrian University of Athens, First Department of Pediatrics, Athens, Greece
